Oral administration of A. muciniphila could inhibit the expansion and inflammation of the abdominal aorta, restore the gut microbiota diversity, promote peripheral blood immunity and IL-33 expression, and regulate the functional pathways related to Lactobacillus and L-rhamnose degradation/synthesis to inhibit the formation of AAA. This evidence concerns the gene IL33 and triple-A syndrome.